ArticleJournal of translational medicine2026
M2 macrophages modulate the differentiation of CD8 + CD101-TIM3 + T cells via the SPP1‒CD44 pathway, influencing the immunotherapeutic response in NSCLC.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrative analysis of single-cell sequencing identifies CD8Translational cancer research · 2026Article
- Research trends in cytokine regulation of immunotherapy in non-small cell lung cancer: a bibliometric and BERTopic analysis from 2015 to 2025.Journal of thoracic disease · 2026Article
- IGLC3Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) patients present greatly different responses to immunotherapy. The main clinical challenge lies in the poor response to immune checkpoint inhibitors (ICIs), and the underlying mechanisms remain unclear.
methodsHere, single-cell RNA sequencing and bulk RNA sequencing data were comprehensively analyzed. Tumour samples from NSCLC patients treated with ICIs were subjected to multiplexed immunofluorescence staining, and PBMCs were extracted from peripheral blood for flow cytometry. Primary cells were isolated from the PBMCs of NSCLC patients for in vitro coculture experiments, and a murine subcutaneous Lewis lung carcinoma (LLC) model was used for in vivo experiments.
resultsThis study proposed the hypothesis that CD8 + CD101 + TIM3 + T cells (CCT T cells) are differentiated from CD8 + CD101-TIM3 + T cells (Pre-CCT T cells). This differentiation process is mediated by M2 macrophages via the SPP1‒CD44 pathway and influences the immunotherapeutic response of NSCLC. Analysis of NSCLC clinical samples revealed that lower proportions of tumour-infiltrating CCT T cells and M2-TAMs were associated with a better immunotherapeutic response. According to in vitro experiments, coculture with M2 macrophages significantly increased the CD101 expression in Pre-CCT T cells, whereas in vivo experiments revealed that the removal of bone marrow-derived M2-TAMs significantly lowered the proportion of CCT T cells, inhibited tumour growth, and improved the response to anti-PD-1 therapy. Besides, blockade of the SPP1‒CD44 pathway remarkably weakened the CD101 expression in Pre-CCT T cells in coculture experiments. Moreover, blockade of the SPP1‒CD44 pathway in vivo significantly inhibited tumour growth and enhanced the response to anti-PD-1 therapy in C57BL/6 mice.
conclusionsOur study provides insights into the promotion of Pre-CCT T-cell differentiation by M2 macrophages through the SPP1‒CD44 pathway and elucidates its important role in anti-PD-1 therapy, thus providing potential strategies for increasing immunotherapy efficacy in NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.